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A B S T R A C T
Introduction: Numerous RCTs have demonstrated the effectiveness of internet-based self-management inter-
ventions (SMIs) in the treatment of depressive symptoms. These studíes often recruit outside routine clinical
practice. For the present study, we investigated the feasibility, effectiveness and safety of an SMI (deprexis) in
routine medical care using a non-interventional design.
Methods: A total of 104 patients with a depressive disorder (60.58% female, mean age 45.82 yrs) were recruited
in 25 outpatient practices in Germany (mostly psychiatric practices, n = 16). They received 12 week access to
the SMI in addition to their usual care (76.0% took concomitant antidepressant medication). Guidance could
optionally be offered by the treating physician. The effectiveness of the intervention was assessed using the
clinician-rated short version of the Montgomery Asberg-Depression Scale (svMADRS) and the Patient Health
Questionnaire (PHQ-9), a self-rating for depressive symptoms. Outcomes were assessed at baseline as well as at
weeks 3, 6, 9 and 12.
Results: Most patients reported using the intervention at least once (n=87, 83.6%), among these users the mean
number of sessions was 18.05 (SD = 11.33). Only a minority of patients received the guided version of the
intervention (n = 7, 8.0%). The severity of depressive symptoms decreased significantly over the observation
period from 29.72 (SD = 10.03) to 15.73 (SD = 9.74) for the svMADRS (Cohen's d = 1.42, 95% CI 0.08–2.76)
and from 15.20 (SD = 5.03) to 8.77 (SD = 5.03) for the PHQ-9 (d = 1.29, 95% CI 0.60–1.97).
Discussion: The size of the pre-post effect on depressive symptoms observed in this study is comparable to the
pre-post effect size reported in an RCT using the same intervention in patients suffering from depressive
symptoms of the same severity. Limitations of this study include the lack of a control group and the fact that the
recruitment rate was far lower than expected.
Conclusion: This non-interventional study conducted in outpatient practices confirms results from numerous
RCTs. Taken together, these data show that deprexis can be used effectively and safely in the routine care of
depressed outpatients.
1. Introduction
Depression is very common but often remains untreated (Jacobi
et al., 2014; Nübel et al., 2019). Reasons for this treatment gap include
structural factors, including long waiting lists. More often, though,
patients with depression or other severe mental disorders name the
desire to solve their problems on their own as a reason for not seeking
treatment (Kessler et al., 2001; Nübel et al., 2019). Internet
interventions might therefore be an opportunity to reduce the treat-
ment gap (Schröder et al., 2016). One group of internet interventions
are self-management interventions (SMI) which are mostly based on
theories and techniques of cognitive behavioural therapy (CBT). SMIs
have been shown to be effective in the treatment of depression
(Karyotaki et al., 2017), resulting in clinically relevant changes
(Karyotaki et al., 2018a) with no evidence of an increased risk of
harmful effects (Karyotaki et al., 2018b).
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One SMI that has been studied in numerous trials, is deprexis®24
(hereafter “deprexis”, for a meta-analysis, see Twomey et al., 2020). In
these trials, this SMI has demonstrated its effectiveness not only in mild
to moderate depression (Klein et al., 2016) but also in severe depression
(Meyer et al., 2015). The intervention has also been used successfully in
patients who suffer from depressive symptoms in the context of mul-
tiple sclerosis (Fischer et al., 2015), epilepsy (Schröder et al., 2014) and
in problem gamblers (Bücker et al., 2018). The participants in most of
these studies were self-selected and recruited outside routine clinical
practice. Two published RCTs of deprexis have examined the effec-
tiveness of blended therapy in routine clinical settings. Here, deprexis
was added to in- and outpatient psychotherapy respectively (Berger
et al., 2018; Zwerenz et al., 2019, 2017).
Other SMIs have also been tested in routine clinical settings.
Randomized clinical trials of these interventions have yielded mixed
results: one study conducted in primary care in Britain found that the
addition of MoodGYM or Beating the Blues to usual primary care did not
convey an added benefit, possibly because the interventions were used
only once (MoodGYM) or twice (Beating the Blues) by most patients
(Gilbody et al., 2015). These results shed some doubt on the feasibility
of using SMIs in routine clinical care and suggest the need of further
studies. Another German study, also conducted in primary care, found
that MoodGYM was more effective than usual care in reducing de-
pressive symptoms; but again only 70% of patients used the interven-
tion (Löbner et al., 2018). Moreover, in a large uncontrolled study
conducted in primary care in Australia, it was found that the treatment
program Sadness worked with large pre-post effect sizes on symptoms of
depression (Williams and Andrews, 2013). Most of the available studies
focussed on the effectiveness of SMIs and only a minority of studies
systematically assess adverse events (Karyotaki et al., 2018b; Moritz
et al., 2019).
For the present study, we have therefore investigated the feasibility,
effectiveness and safety of the SMI deprexis using an observational
design. We have put particular emphasis on assessing adverse events. In
the spirit of an effectiveness trial, we have recruited only patients who




This is a single-group, uncontrolled, prospective observational study
of adult patients with a depressive disorder (either dysthymia or de-
pressive episode) who were starting treatment with deprexis as part of
their routine medical care. Patients were recruited in Germany through
the following outpatient services: general practicioners (n = 4), neu-
rologists (n = 5) and psychiatrists (n= 16) between October 2016 and
February 2018. To enhance external validity, all patients could be in-
cluded into this study regardless of presence or absence of comorbid
disorders or concurrent medication. The trial was approved by an Ethics
Committee Freiburg (016/1259) and is registered with German Trials
Register (DRKS00011628). Written informed consent was obtained
prior to the baseline assessment. The full study protocol has been laid
down in writing before the initiation of patient recruitment and is
available upon request. The following change has been made to the
protocol after the initiation of the trial: the initial goal was to recruit up
to 1800 patients to the trial, but recruitment was stopped after in-
cluding only 104 patients because recruitment was much slower than
anticipated and the duration of recruitment had already been extended
from 9 months to 17 months.
2.2. Intervention
All participants received access to the deprexis for 12 weeks in
addition to their usual care (for more information on the actual care
received, please see the Results section). Access to deprexis was pro-
vided at a reduced cost of 179 € (instead of 297.50 €) because deprexis
was not part of regular care in the German health care system when the
study was conducted (some insurance companies did cover the cost,
however). The content of deprexis is broadly consistent with the prin-
ciples of CBT. It is divided into six to ten modules ranging from beha-
vioural activation and cognitive modification to dreamwork and is in-
dividually tailored to the user. The number and order of modules as
well as its depth and breadth can vary depending on the user's pre-
ferences (for example, the “interpersonal skills” module is offered to
some patients while the “behavioural activation” module is offered to
all patients). It is recommended that users complete one to two sessions
of about 30 min per week (for more details, see Meyer et al., 2009 and
Twomey et al., 2017). The intervention can be used with or without
guidance by a clinician (Berger et al., 2011). For the guided version,
messages can be sent through a secure email-system embedded within
the internet intervention. In our trial, the guided version could be of-
fered by the treating physician (but it was not routinely offered). Fre-
quency and content of guidance were not influenced by the study team.
2.3. Outcome measures
The usage of the intervention was measured using patient self-re-
port. Note that the number of sessions does not necessarily reflect the
number of completed modules because it can take more than one ses-
sion to complete a module. The effectiveness of the intervention was
assessed using the clinician-rated short version of the Montgomery
Asberg-Depression Scale (svMADRS: Montgomery and Asberg, 1979)
and the Patient Health Questionnaire (PHQ-9: Kroenke et al., 2010), a
self-rating for depressive symptoms. Higher scores on the svMADRS and
the PHQ-9 reflect higher severity of depressive symptoms. Clinicians
also completed the Clinical Global Impression (CGI) score and patients
also completed the Sheehan Disability Scale (SDS: Sheehan and
Sheehan, 2008) and the Client Satisfaction Questionnaire (CSQ-4:
Attkisson and Greenfield, 2004). For the SDS, higher scores reflect more
severe disability in work, social and family life; for the CSQ-4, higher
scores are associated with greater satisfaction. Patients also completed
two items from the Compulsive Internet Use Scale (CIUS: Besser et al.,
2017). The time reference for these scales was the past two weeks
(expect for the svMADRS and the lost days subscale of the SDS, here it
was one week). All outcomes were determined at baseline as well as at
weeks 3, 6, 9 and 12. At these assessment time points, physicians also
assessed the patients' medication status and completed standardized
adverse events forms to document safety-relevant incidents and adverse
events.
2.4. Statistical analysis
Statistical analysis was performed by a contract research organiza-
tion (ANFOMED GmbH, Germany) using SAS™ following a previously
agreed upon statistical analysis plan (SAP). Missing values were re-
placed using last observation carried forward if at least two entries were
made for this variable, i.e. the baseline value and at least one value
after baseline (modified intention to treat analysis). This was used as a
conservative estimate of actual symptom course because many patients
show improvement even in untreated depression (Cuijpers et al., 2020).
All statistical tests should be interpreted in a descriptive-explorative
way and are reported as two-tailed tests with an p-value of< 0.05 used
to assess statistical significance. Wilcoxon's signed-rank tests were cal-
culated for continuous variables and Bhapkar's Test of marginal
homogeneity was used for nominal variables.




A total of 104 patients with a depressive disorder were recruited in
24 centres (mean patients/centre = 3.46, SD = 4.91). Retention rate
was 92.3% (n = 96), 86.5% (n = 90) and 84.6% (n = 88) at the as-
sessment weeks 3, 6, 9 and 12 respectively. Participants were pre-
dominantly female (60.58%, n = 63), they had a mean age 45.82 yrs.
(SD = 12.2) and only 29.81% (n = 31) had completed highest sec-
ondary education (37.68%, n= 39 were employed full-time). A total of
30 patients (28.8%) reported using private use of the internet for more
than 2 h per day.
3.2. Clinical characteristics
A total of 44 patients (42.3%) met criteria for a first depressive
episode, 49 patients (47.1%) had a recurrent depressive disorder and 8
(7.7%) patients were diagnosed with dysthymia. The mean number of
previous depressive episodes was 4.54 (SD = 4.76), the mean duration
of the current depressive episode was 18.05 weeks (SD = 31.16).
Regarding further indices of chronicity, the treating physicians reported
that 47.5% of patients (n= 48) had not experienced remission for more
than two years and that 70.6% (n = 72) had first experienced de-
pression before the age of 21.
A past history of suicide attempt was reported by 11 patients
(10.7%). According to the treating physician, a total of 46 patients
(44.2%) had comorbid psychiatric disorders, mostly anxiety disorders
(26%, n= 27) and substance dependence (9.6%, n= 10); and a total of
46 patients (44.2%) had comorbid somatic disorders (e.g. metabolic
disorder, gastrointestinal disorder or cardiovascular disorder). With
respect to treatment history, 70,9% (n = 73) had previously been
treated with an antidepressant (38.5% used an SSRI, n = 40; 26.4%
were treatment-resistant, n = 23) and 33.7% (n = 35) had received
psychotherapy in the past months (mostly cognitive behaviour therapy,
n= 17, and psychodynamic therapy, n= 13). At baseline, 76.0% were
taking antidepressant medication (n = 79; n = 40, 38.5% were on an
SSRI) and 33.6% were in psychotherapy (n = 35).
3.3. Intervention usage
Most patients reported using the intervention at least once (n= 87,
83.6%), among these users the mean number of sessions was 18.05
(SD = 11.33). A total of 20.2% (n= 21) were coded as terminating the
use of the intervention prematurely; but this number includes loss-to-
follow-up (n= 7) as well as lack of compliance (n= 5) and inadequate
internet access (n = 3). Most patients reported spending between 30
and 60 min per session (n= 51, 63.0% at week three, n= 47, 58.1% at
week six, and n = 50, 63.3% at week twelve). Only a minority of pa-
tients received the guided version of the intervention (n = 7, 8.0%).
3.4. Clinical outcome
All clinical outcomes for all assessment time points are presented in
Table 1. Briefly, the severity of depressive symptoms decreased sig-
nificantly over the observation period from 29.72 (SD = 10.03) at
baseline to 15.73 (SD = 9.74) at week 12 for the clinician-rated
svMADRS (p < .0001, Cohen's d = 1.42, 95% CI 0.08–2.76) and from
15.20 (SD = 5.03) to 8.77 (SD = 5.03) for the patient-rated PHQ-9
(p < .0001, d = 1.29, 95% CI 0.60–1.97). With regard to functional
impairment in social life, the total score on the SDS significantly de-
creased from 19.90 (SD = 6.54) at baseline to 11.36 (SD = 6.34) at
week 12 (p < .0001, d= 1.33, 95% CI 0.38–2.28). Also, the clinician-
rated severity of illness as assessed by the CGI decreased significantly
from 69 patients (67.0%) being rated as markedly ill or worse at
baseline to only 9 patients (10.2%) at week 12 (p < .0001, RR= 0.15,
95% CI 0.08–0.29); 28.9% (n = 28) were rated as “very much im-
proved” and 42,3% (n = 41) as “much improved” at week 12.
3.5. Patient satisfaction
On the CSQ-4, the sum score at week 12 was 12.36 (SD= 2.12) out
of a total of 16 points. More specifically, 55 patients (68.75%) reported
that “most (or all) of my needs have been met”, 75 answered that the
intervention “helped (a great deal)” (93.75%) and 69 patients said they
would (definitely) use the intervention again (86.25%).
3.6. Adverse events
Two adverse incidents (feeling of paralysis and increase in depres-
sive symptoms) and one serious adverse event (acute suicidality) were
reported by the treating physicians. Only the feeling of paralysis was
considered to be causally related to deprexis by the treating physician.
The patient reporting an increase in depressive symptoms felt over-
whelmed by deprexis. Consequently, treatment with the intervention
and participation in the study were terminated. The other two patients
were followed up and were reported as recovering (suicidality) and
recovered (paralysis spontaneously recovered after a few hours).
3.7. Internet usage
Self-reported total internet usage did not change substantially
during the study period: the number of patients who reported private
use of the internet for 2 h or more per day increased slightly from 30
(28.8%) at baseline to 33 (35.5%) at week three and decreased there-
after to 23 (25.8%) at week six and 18 (21.2%) at week twelve.
Likewise the number of patients who reported that they often or very
often continued using the internet even though they actually wanted to
quit decreased from 23 (22.1%) at baseline, to 19 (20.7%) at week
three, 9 (10.0%) at week six and 6 (7.1%) at week twelve. The same
was true for the number of patients reporting that they often or very
often neglected obligations because of spending time on the internet,
this decreased from 9 (8.6%) at baseline, to 8 (8.7%) at week three, 4
(4.4%) at week six and 4 (4.7%) at week twelve.
4. Discussion
This observational study in depressed patients treated in routine
care remained far below the recruitment target. It found that the usage
intensity of deprexis was adequate and associated with improvement in
range of outcomes: a decrease in both clinician- and self-rated depres-
sive symptoms, a decrease in disability and an increase in global
functioning. Only a small minority of patients experienced adverse
events. We also found a decrease of uncontrolled internet use over time
suggesting that treatment with deprexis was not associated with the
emergence of symptoms of internet use disorder. This is a reassuring
finding given that symptoms of depression are strongly associated with
problematic internet use (Carli et al., 2013).
One central limitation of this study is that actual recruitment fell far
short of the recruitment target. This is probably due to the fact that in
contrast to other clinical studies, some participants in this study had to
pay for the use of deprexis (albeit at a somewhat reduced price) because
in Germany, SMIs were not covered by the statuatory health insurance
then. This has changed in 2020, however, with the advent of the Digital
Care Act (Digitales Versorgungsgesetz) which provides that certain in-
ternet interventions can be listed and reimbursed by the statuatory
health insurance (Geirhos et al., 2019). Other RCTs that aimed to re-
cruit in routine clinical settings had similar problems, even if the SMI
was offered at no cost to patients (Berger et al., 2018; Klein et al.,
2017). This suggests that clinicians and patients do not yet routinely
consider SMIs as an option along with the more traditional treatment
options (i.e. psychotherapy and psychopharmacotherapy). This may
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change as the physical distancing necessitated by the COVID-19 pan-
demic could lead to a sustained shift of mental health provision toward
online treatment (Wind et al., 2020). Our recruitment difficulties
somewhat limit the generalizability of our findings as patients who
were highly motivated to use the intervention might have been more
willing to pay for it. On the other hand, we have observed even higher
usage intensities in previous RCTs where the intervention was provided
at no cost to the participants (Klein et al., 2016; Meyer et al., 2015). It
should also be noted that intervention usage was assessed by patients'
self-reports and these may not be an accurate representation of actual
adherence (Flett et al., 2019).
Furthermore, our study has an observational design and the ob-
served decrease in depressive symptoms can therefore not be directly
attributed to the use of the intervention. Observational studies are
therefore considered lower quality evidence (Johnson et al., 2016).
Numerous RCTs exist however that demonstrate the efficacy of deprexis
(Twomey et al., 2020) and the pre-post effect size observed for the
reduction of depressive symptoms in this study is comparable to the
pre-post effect size reported in an RCT using deprexis in patients suf-
fering from depressive symptoms of the same severity (Meyer et al.,
2015). The observational design of our study offers the advantage of
better generalizability of the findings to routine care because certain
patients may not want to undergo randomization and therefore the
study sample in an RCT may not be representative of the target popu-
lation (Stuart et al., 2015). In fact, while the samples of our previous
RCTs of deprexis were quite highly educated (Klein et al., 2016; Meyer
et al., 2015), the level of education in the sample presented here comes
closer to the general population with only one third having completed
highest secondary education (Späth et al., 2017).
It could be argued that our intervention was a blended therapy
because patients did not only use deprexis but also saw a clinician on a
regular basis. In its broadest sense, blended therapy refers to any type of
face-to-face treatment that is augmented with a digital intervention.
More precisely, it can be subdivided into adjunctive treatments and
highly integrated treatments (Schuster et al., 2020). The treatment
format applied in our study can therefore be referred to as “adjunctive
blended therapy”. Its results confirm results of RCTs where deprexis
was offered in adjunct to psychotherapy, either in inpatient (Zwerenz
et al., 2017) or outpatient setting (Berger et al., 2018): the pre-post
effect size in our study was slightly larger than the pre-post effect sizes
in the adjunctive therapy group in these RCTs.
In conclusion, our non-interventional study conducted in outpatient
practices confirms results from numerous RCTs. Taken together, these
data show that depressed patients use deprexis adequately with a large
effect on their depressive symptomatology and no evidence of adverse
events. The low recruitment rate however points to further needs re-
garding the dissemination of SMIs.
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Individual participant data that underlie the results reported in this
Table 1
Clinical outcomes.
Baseline Week 3 Week 6 Week 12
PHQ-9 (n = 95) 15.20 5.03 12.95 4.82 10.53 4.55 8.77 5.03
svMADRS (n = 82) 29.72 10.03 26.46 9.85 20.66 8.99 15.73 9.74
SDS (n = 87)
Total score 19.90 6.54 18.07 5.89 14.67 5.99 11.36 6.34
Occupational 6.67 2.53 6.06 2.35 5.11 2.47 3.91 2.33
Social life 6.74 2.51 6.23 2.22 5.00 2.19 3.87 2.35
Family/home 6.49 2.39 5.76 2.16 4.55 2.06 3.57 2.21
Lost days 4.09 2.86 3.81 2.68 3.35 2.44 2.40 2.11
CGI-S (n = 85)
Normal 2 2.3% 3 3.4%
Borderline ill 1 1.1% 3 3.4% 10 11.4%
Mildly ill 8 7.8% 9 9.6% 16 18.0% 35 40.0%
Moderately ill 26 25.2% 32 34.0% 52 58.4% 31 35.2%
Markedly ill 46 44.7% 43 45.7% 14 15.7% 9 10.2%
Severely ill 19 18.5% 9 9.57% 2 2.5%
Extremely ill 4 3.9%
CSQ-4 (n = 81) n.a. 12.36 2.12
Clinical outcomes are reported as means (standard deviations) and numbers (%) respectively. Missing values were replaced using last observation carried forward if
at least two entries were made for this variable, i.e. the baseline value and at least one value after baseline (modified intention to treat analysis). Therefore, the total
number of observations differs from the number of included participants. CGI-S: Clinical Global Impression-Severity, CSQ-4: Client Satisfaction Questionnaire, PHQ-
9: Patient Health Questionnaire, SDS: Sheehan Disability Scale, sVMADRS: short version of the Montgomery Asberg Depression Rating Scale.
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